Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sotirios Tsimikas MD, FACC, FAHA, FSCAI

Sotirios Tsimikas MD, FACC, FAHA, FSCAI

Professor of Medicine/Cardiology and Director of Vascular Medicine, Sulpizio Cardiovascular Center, Division of Cardiovascular Medicine, University of California San Diego, La Jolla, California

Dr. Tsimikas is Professor of Medicine and Director of Vascular Medicine at the University of California San Diego School of Medicine. He obtained his MD degree from the University of Massachusetts Medical School in 1988, completed Internal Medicine training at the University of Massachusetts Medical Center in 1991, and fellowships in Cardiovascular Disease, Atherosclerosis and Molecular Medicine and Interventional Cardiology at the University of California San Diego from 1992-1997. He is fellow of the American College of Cardiology, American Heart Association and Society of angiography and Intervention. Dr. Tsimikas clinical interests are in Interventional Cardiology and in lipid disorders, particularly in Lp(a). In 2014, he established the world’s first dedicated “Lp(a) Clinic”. He teaches on atherosclerosis to UCSD Medical students. His research interests focus on: 1-“biotheranostics”- biomarkers, molecular imaging and therapeutics targeted to oxidation-specific epitopes; and 2-Lp(a) pathophysiology and therapeutics. He is co-inventor and developer of the OxPL-apoB assay, which is the focus of 53 original scientific publications and 25 review articles. He has spearheaded clinical development and clinical trials of several antisense oligonucleotides, including to apoC-III, Lp(a), ANGPTL3, and angiotensinogen, one of which is approved in Europe and others are in phase 2-3 trials. He has published in all of the major medical journals, including NEJM, Lancet, Nature, Cell, JACC, Circulation, Circulation Research, European Heart Journal, ATVB, JAMA Cardiology and has published over 280 original manuscripts, review articles and book chapters. His works have been cited over 11,900 times and he has an H-index of 63.


Dr. Tsimikas is a co-inventor of and receive royalties from patents or patent applications owned by the University of California San Diego on oxidation-specific epitope; is co-founder of Oxitope, Inc., and Kleanthi Diagnostics; is a consultant to Boston Heart Diagnostics; and has a dual appointment at UCSD and Ionis Pharmaceuticals, Inc.